Dietary supplementation with branched-chain amino acids suppresses diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db mice

Cancer Science

Volumn 101, Issue 2, 2010, Pages 460-467

  Iwasa, Junpei ^a   Shimizu, Masahito ^a   Shiraki, Makoto ^a   Shirakami, Yohei ^a   Sakai, Hiroyasu ^a   Terakura, Yoichi ^a   Takai, Koji ^a   Tsurumi, Hisashi ^a   Tanaka, Takuji ^b   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BRANCHED CHAIN AMINO ACID; CASEIN; DIETHYLNITROSAMINE; LEPTIN; SOMATOMEDIN B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PREVENTION; CELL PROLIFERATION; CONTROLLED STUDY; DIABETES MELLITUS; DIET SUPPLEMENTATION; FATTY LIVER; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HYPERLEPTINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER ADENOMA; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER TUMOR; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL;

ALANINE TRANSAMINASE; AMINO ACIDS, BRANCHED-CHAIN; ANIMALS; DIABETES COMPLICATIONS; DIETARY SUPPLEMENTS; DIETHYLNITROSAMINE; INSULIN RESISTANCE; LEPTIN; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; OBESITY;

EID: 75649149159     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01402.x     Document Type: Article

References (46)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-76.
2. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003, 348:1625-38.
3. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006, 4:369-80.
4. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004, 126:460-8.
5. Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med 2008, 14:72-81.
6. Saadeh S. Nonalcoholic Fatty liver disease and obesity. Nutr Clin Pract 2007, 22:1-10.
7. Smedile A, Bugianesi E. Steatosis and hepatocellular carcinoma risk. Eur Rev Med Pharmacol Sci 2005, 9:291-3.
8. Day CP, James OF. Steatohepatitis: a tale of two " hits" ? Gastroenterology 1998, 114:842-5.
9. Lee GH, Proenca R, Montez JM. Abnormal splicing of the leptin receptor in diabetic mice. Nature 1996, 379:632-5.
10. Scheen AJ, Luyckx FH. Obesity and liver disease. Best Pract Res Clin Endocrinol Metab 2002, 16:703-16.
11. Hirose Y, Hata K, Kuno T. Enhancement of development of azoxymethane-induced colonic premalignant lesions in C57BL/KsJ-db/db mice. Carcinogenesis 2004, 25:821-5.
12. Sahai A, Malladi P, Pan X. Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am J Physiol Gastrointest Liver Physiol 2004, 287:G1035-43.
13. Shimizu M, Shirakami Y, Sakai H. (-)-Epigallocatechin gallate suppresses azoxymethane-induced colonic premalignant lesions in male C57BL/KsJ-db/db mice. Cancer Prev Res 2008, 1:298-304.
14. Kawaguchi T, Nagao Y, Matsuoka H, Ide T, Sata M. Branched-chain amino acid-enriched supplementation improves insulin resistance in patients with chronic liver disease. Int J Mol Med 2008, 22:105-12.
15. Marchesini G, Bianchi G, Merli M. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology 2003, 124:1792-801.
16. Muto Y, Sato S, Watanabe A. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 2005, 3:705-13.
17. Shimizu M, Shirakami Y, Iwasa J. Supplementation with branched-chain amino acids inhibits azoxymethane-induced colonic preneoplastic lesions in male C57BL/KsJ-db/db mice. Clin Cancer Res 2009, 15:3068-75.
18. Muto Y, Sato S, Watanabe A. Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res 2006, 35:204-14.
19. Alexia C, Fallot G, Lasfer M, Schweizer-Groyer G, Groyer A. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochem Pharmacol 2004, 68:1003-15.
20. Shimizu M, Shirakami Y, Sakai H. EGCG inhibits activation of the insulin-like growth factor (IGF)/IGF-1 receptor axis in human hepatocellular carcinoma cells. Cancer Lett 2008, 262:10-8.
21. Frith CH, Ward JM, Turusov VS, Turusor VS, Mohr U. Tumours of the liver. Pathology of Tumors in Laboratory Animals 1994, 223-70. In, eds, Vol 2, Lyon, IARC Scientific Publications
22. Yasuda Y, Shimizu M, Sakai H. (-)-Epigallocatechin gallate prevents carbon tetrachloride-induced rat hepatic fibrosis by inhibiting the expression of the PDGFR and IGF-1R. Chem Biol Interact 2009, 182:159-64.
23. Shimizu M, Hara A, Okuno M. Mechanism of retarded liver regeneration in plasminogen activator-deficient mice: impaired activation of hepatocyte growth factor after Fas-mediated massive hepatic apoptosis. Hepatology 2001, 33:569-76.
24. Shiraki M, Shimomura Y, Miwa Y. Activation of hepatic branched-chain alpha-keto acid dehydrogenase complex by tumor necrosis factor-alpha in rats. Biochem Biophys Res Commun 2005, 328:973-8.
25. Suzuki R, Kohno H, Yasui Y. Diet supplemented with citrus unshiu segment membrane suppresses chemically induced colonic preneoplastic lesions and fatty liver in male db/db mice. Int J Cancer 2007, 120:252-8.
26. Katz A, Nambi SS, Mather K. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000, 85:2402-10.
27. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957, 226:497-509.
28. Tomita H, Yamada Y, Oyama T. Development of gastric tumors in Apc(Min/+) mice by the activation of the beta-catenin/Tcf signaling pathway. Cancer Res 2007, 67:4079-87.
29. Kang S, Song J, Kang H, Kim S, Lee Y, Park D. Insulin can block apoptosis by decreasing oxidative stress via phosphatidylinositol 3-kinase- and extracellular signal-regulated protein kinase-dependent signaling pathways in HepG2 cells. Eur J Endocrinol 2003, 148:147-55.
30. Tornkvist A, Parpal S, Gustavsson J, Stralfors P. Inhibition of Raf-1 kinase expression abolishes insulin stimulation of DNA synthesis in H4IIE hepatoma cells. J Biol Chem 1994, 269:13919-21.
31. Nishitani S, Takehana K. Pharmacological activities of branched-chain amino acids: augmentation of albumin synthesis in liver and improvement of glucose metabolism in skeletal muscle. Hepatol Res 2004, 30S:19-24.
32. Nishitani S, Takehana K, Fujitani S, Sonaka I. Branched-chain amino acids improve glucose metabolism in rats with liver cirrhosis. Am J Physiol Gastrointest Liver Physiol 2005, 288:G1292-300.
33. Doi M, Yamaoka I, Nakayama M, Sugahara K, Yoshizawa F. Hypoglycemic effect of isoleucine involves increased muscle glucose uptake and whole body glucose oxidation and decreased hepatic gluconeogenesis. Am J Physiol Endocrinol Metab 2007, 292:E1683-93.
34. Urata Y, Okita K, Korenaga K, Uchida K, Yamasaki T, Sakaida I. The effect of supplementation with branched-chain amino acids in patients with liver cirrhosis. Hepatol Res 2007, 37:510-6.
35. Marchesini G, Brizi M, Bianchi G. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001, 50:1844-50.
36. Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. Hepatology 2005, 42:5-13.
37. Moriya K, Fujie H, Shintani Y. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998, 4:1065-7.
38. Moriya K, Yotsuyanagi H, Shintani Y. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 1997, 78:1527-31.
39. Shintani Y, Fujie H, Miyoshi H. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004, 126:840-8.
40. Ohata K, Hamasaki K, Toriyama K. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003, 97:3036-43.
41. Ikejima K, Takei Y, Honda H. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 2002, 122:1399-410.
42. Leclercq IA, Farrell GC, Schriemer R, Robertson GR. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 2002, 37:206-13.
43. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008, 134:1655-69.
44. Yamaguchi K, Yang L, McCall S. Diacylglycerol acyltranferase 1 anti-sense oligonucleotides reduce hepatic fibrosis in mice with nonalcoholic steatohepatitis. Hepatology 2008, 47:625-35.
45. Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 2007, 132:2208-25.
46. Yoshiji H, Noguchi R, Kitade M. Branched-chain amino acids suppress insulin-resistance-based hepatocarcinogenesis in obese diabetic rats. J Gastroenterol 2009, 44:483-91.